Share Twitter LinkedIn Facebook Email Michael Korn, MD, CMO of Caris Life Sciences discusses the enrichment of alterations in targetable molecular pathways in KRAS wild-type pancreatic cancer. Read here: https://meetinglibrary.asco.org/record/186629/abstract Advertisement
Revolutionizing Pancreatic Cancer Detection: The Groundbreaking Role of Liquid Biopsies – Ajay Goel, PhD [AACR 2024] Pancreatic 3 Mins Read